Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

September 24, 2019

Conditions
Postoperative Pain Management
Interventions
DRUG

Exparel

EXPAREL 4mg/kg (maximum 266 mg)

DRUG

0.5% Bupivacaine HCl

Bupivacaine HCl 2mg/kg

Trial Locations (17)

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Nemours / Alfred I. DuPont Hospital for Children, Wilmington

27157

Wake Forest Baptist Health, Winston-Salem

27710

Duke University Medical Center, Durham

33155

Nicklaus Children's Hospital, Miami

44195

Cleveland Clinic, Cleveland

46204

Riley Hospital for Children at Indiana University Health, Indianapolis

53226

Children's Hospital of Wisconsin, Milwaukee

55454

University of Minnesota Masonic Children's Hospital, Minneapolis

60707

Shriners Hospitals for Children-Chicago, Chicago

73110

University of Oklahoma Health Sciences Center, Oklahoma City

75075

Southwest Scoliosis Institute, Plano

77030

McGovern Medical School at UTHealth, Houston

80045

Children's Hospital Colorado, Aurora

92354

Loma Linda University, Loma Linda

94305

Stanford University, Stanford

95817

Shriners Hospitals for Children, Northern California, Sacramento

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY